$0.00
46.00% yesterday
Nasdaq, Sep 27, 09:50 pm CET
ISIN
US83587F2020
Symbol
SRNE
Sector
Industry

Sorrento Therapeutics, Inc. Stock price

$0.00
-0.01 70.00% 1M
-0.01 66.25% 6M
-0.12 97.81% YTD
-0.09 97.03% 1Y
-8.14 99.97% 3Y
-2.16 99.88% 5Y
-4.43 99.94% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.00 46.00%
ISIN
US83587F2020
Symbol
SRNE
Sector
Industry

Key metrics

Market capitalization $2.76m
Enterprise Value $136.88m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.13
P/S ratio (TTM) P/S ratio 0.04
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 16.89%
Revenue (TTM) Revenue $64.27m
EBIT (operating result TTM) EBIT $-355.52m
Free Cash Flow (TTM) Free Cash Flow $-243.21m
Cash position $80.64m
EPS (TTM) EPS $-1.06
Short interest 11.96%
Show more

Is Sorrento Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Sorrento Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Sorrento Therapeutics, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Sorrento Therapeutics, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Sorrento Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '23
+/-
%
64 64
17% 17%
100%
- Direct Costs 40 40
66% 66%
62%
24 24
22% 22%
38%
- Selling and Administrative Expenses 174 174
1% 1%
271%
- Research and Development Expense 186 186
16% 16%
290%
-336 -336
8% 8%
-523%
- Depreciation and Amortization 19 19
11% 11%
30%
EBIT (Operating Income) EBIT -356 -356
7% 7%
-553%
Net Profit -548 -548
5% 5%
-853%

In millions USD.

Don't miss a Thing! We will send you all news about Sorrento Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sorrento Therapeutics, Inc. Stock News

Neutral
Business Wire
7 months ago
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Neutral
PRNewsWire
about one year ago
SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "the Debtor"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the "Bankr...
Negative
Seeking Alpha
more than one year ago
Scilex is majority owned by Sorrento, a company I will not invest in. Scilex is a more regular company, doing R&D work, selling drugs and so on. However, it is still entangled with Sorrento, and its stock price movement is too erratic for me.
More Sorrento Therapeutics, Inc. News

Company Profile

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.

Head office United States
CEO Henry Ji
Founded 1989
Website sorrentotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today